CTI BioPharma Corp. (NASDAQ:CTIC – Get Rating) shares hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $9.05 and last traded at $9.00, with a volume of 1134712 shares changing hands. The stock had previously closed at $8.93.
Analyst Ratings Changes
CTIC has been the subject of a number of recent analyst reports. Stifel Nicolaus lowered shares of CTI BioPharma from a “buy” rating to a “hold” rating in a research report on Monday, May 15th. Needham & Company LLC lowered shares of CTI BioPharma from a “buy” rating to a “hold” rating in a research report on Wednesday, May 10th. Lake Street Capital lowered shares of CTI BioPharma from a “buy” rating to a “hold” rating in a research report on Wednesday, May 10th. SVB Securities lowered shares of CTI BioPharma from an “outperform” rating to a “market perform” rating in a research report on Tuesday, May 16th. Finally, TD Cowen reduced their price objective on shares of CTI BioPharma from $10.00 to $8.00 and set an “outperform” rating for the company in a research report on Monday, April 17th. Six equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, CTI BioPharma has a consensus rating of “Hold” and a consensus target price of $10.29.
CTI BioPharma Stock Up 0.1 %
The company has a market capitalization of $1.19 billion, a PE ratio of -15.52 and a beta of 0.86. The business’s 50 day simple moving average is $5.44 and its 200 day simple moving average is $5.52.
Institutional Trading of CTI BioPharma
A number of hedge funds have recently made changes to their positions in CTIC. Bank of America Corp DE lifted its position in shares of CTI BioPharma by 354.5% in the first quarter. Bank of America Corp DE now owns 5,900 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 4,602 shares in the last quarter. Simplicity Solutions LLC purchased a new stake in shares of CTI BioPharma in the first quarter worth approximately $43,000. Shell Asset Management Co. bought a new position in CTI BioPharma during the fourth quarter valued at approximately $47,000. Legal & General Group Plc bought a new position in CTI BioPharma during the second quarter valued at approximately $49,000. Finally, Lazard Asset Management LLC bought a new position in CTI BioPharma during the third quarter valued at approximately $57,000. 99.40% of the stock is owned by hedge funds and other institutional investors.
CTI BioPharma Company Profile
CTI BioPharma Corp. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. It focuses on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis.
- Get a free copy of the StockNews.com research report on CTI BioPharma (CTIC)
- Toll Brothers Rises On Results, But The Roof Is In Place
- It’s Time To Try On VF Corporation’s 6% Yield
- PetCo Management Getting it Right? Earnings Beat Says Yes
- Axcelis Stock In Buy Range After Chart Breakout, Strong Guidance
- Kohl’s 10% Yield Comes Into High Fashion
Receive News & Ratings for CTI BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.